An Open-Label, 2-Period, Fixed Sequence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder), with and without Concomitant Itraconazole in Healthy Adult Subjects.

Albrecht D, Hussey E, Lipton RB

Open source

DOI
10.1002/jcph.70239
Published
2026 Aug
Container
Journal of clinical pharmacology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1002/jcph.70239,
  title = {An Open-Label, 2-Period, Fixed Sequence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder), with and without Concomitant Itraconazole in Healthy Adult Subjects.},
  author = {Albrecht D and Hussey E and Lipton RB},
  year = {2026},
  journal = {Journal of clinical pharmacology},
  doi = {10.1002/jcph.70239},
  url = {https://doi.org/10.1002/jcph.70239}
}

RIS

TY  - JOUR
TI  - An Open-Label, 2-Period, Fixed Sequence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder), with and without Concomitant Itraconazole in Healthy Adult Subjects.
AU  - Albrecht D
AU  - Hussey E
AU  - Lipton RB
PY  - 2026
JO  - Journal of clinical pharmacology
DO  - 10.1002/jcph.70239
UR  - https://doi.org/10.1002/jcph.70239
ER  - 

APA

D, A., E, H., & RB, L. (2026). An Open-Label, 2-Period, Fixed Sequence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder), with and without Concomitant Itraconazole in Healthy Adult Subjects.. Journal of clinical pharmacology. https://doi.org/10.1002/jcph.70239

Source records